VITEK 2 AST-Gram Negative Polymyxin B (<= 0.25 – >=16µg/mL);VITEK 2 AST-Gram Negative Imipenem (<= 0.25 – >=16µg/mL);VITEK 2 AST-Gram Negative Ceftazidime Avibactam (<= 0.125 – >=16µg/mL)

K262807 · BIOMERIEUX, Inc. · LON · Nov 4, 2026 · Microbiology

Device Facts

Record IDK262807
Device NameVITEK 2 AST-Gram Negative Polymyxin B (<= 0.25 – >=16µg/mL);VITEK 2 AST-Gram Negative Imipenem (<= 0.25 – >=16µg/mL);VITEK 2 AST-Gram Negative Ceftazidime Avibactam (<= 0.125 – >=16µg/mL)
ApplicantBIOMERIEUX, Inc.
Product CodeLON · Microbiology
Decision DateNov 4, 2026
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 866.1645
Device ClassClass 2
AttributesPCCP

Indications for Use

VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL) is designed for antimicrobial susceptibility testing of Gram-negative bacilli and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL) is a quantitative test. Testing is indicated for Acinetobacter spp., Enterobacterales, and Pseudomonas aeruginosa as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL) has demonstrated acceptable performance with the following organism: Pseudomonas aeruginosa. The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic Gram negative bacilli to antimicrobial agents when used as instructed. VITEK 2 AST-Gram Negative Imipenem (≤0.25 – ≥16 μg/mL) is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK 2 Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 AST-Gram Negative Imipenem (≤0.25 – ≥16 μg/mL) is a quantitative test. Testing is indicated for Acinetobacter spp., Enterobacterales, and Pseudomonas aeruginosa as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). VITEK 2 AST-Gram Negative Imipenem (≤0.25 – ≥16 μg/mL) has demonstrated acceptable performance with the following organisms: Acinetobacter spp. (Acinetobacter baumannii, Acinetobacter baumannii complex), Enterobacterales (Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Enterobacter cloacae complex, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Klebsiella pneumoniae ssp. ozaenae, Klebsiella pneumoniae ssp. pneumoniae, Lelliottia amnigena, Pantoea despersa, Pseudescherichia vulneris, Raoultella ornithinolytica), Pseudomonas aeruginosa. The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic Gram negative bacilli to antimicrobial agents when used as instructed. VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 – ≥16 μg/mL) is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK 2 Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 – ≥16 μg/mL) is a quantitative test. Testing is indicated for Enterobacterales, and Pseudomonas aeruginosa as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 – ≥16 μg/mL) has demonstrated acceptable performance with the following organisms: Enterobacterales (Citrobacter freundii, Citrobacter koseri, Edwardsiella tarda, Enterobacter cloacae, Enterobacter cloacae ssp. cloacae, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Klebsiella pneumoniae ssp. pneumoniae, Morganella morganii, Morganella morganii ssp. morganii, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Serratia marcescens), Pseudomonas aeruginosa. The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic Gram negative bacilli to antimicrobial agents when used as instructed.

Device Story

Automated antimicrobial susceptibility testing (AST) system; utilizes VITEK 2, VITEK 2 Compact, or VITEK COMPACT PRO instruments. Input: isolated bacterial colonies in saline suspension. Process: automated or manual inoculation of 64-well AST cards; incubation; optical measurement of light attenuation (transmittance) every 15 minutes to monitor growth. Output: MIC values and interpretive category results (S/I/R). Used in clinical laboratories by technicians/microbiologists. Benefits: standardized, rapid, automated determination of antibiotic susceptibility to guide clinical treatment decisions.

Clinical Evidence

Bench testing only. Reanalysis of clinical and challenge data from previous submissions (K193567, K183415, K172944). Combined datasets included hundreds of isolates (e.g., 362 for Polymyxin B, 543 for Imipenem, 1045 for Ceftazidime/Avibactam). Primary endpoints: Essential Agreement (EA) and Category Agreement (CA) against CLSI broth microdilution reference method. EA ranged from 94.8% to 98.6%; CA ranged from 91.0% to 100%. Adjusted error rates were calculated where necessary due to lack of intermediate breakpoints.

Technological Characteristics

64-well AST cards containing nutrient media and premeasured antimicrobials. Sensing principle: optical scanner measuring light transmittance (growth-based). Connectivity: VITEK 2 system software (v11.0). Sterilization: not specified. Software: automated growth analysis algorithm.

Indications for Use

Indicated for antimicrobial susceptibility testing of clinically significant aerobic Gram-negative bacilli (Acinetobacter spp., Enterobacterales, Pseudomonas aeruginosa) to determine MIC values for Polymyxin B, Imipenem, and Ceftazidime/Avibactam. For prescription use in clinical laboratories.

Regulatory Classification

Identification

A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.

Special Controls

*Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”

Predicate Devices

Submission Summary (Full Text)

{1} [LOGO] FDA U.S. FOOD & DRUG ADMINISTRATION # 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION ## DECISION SUMMARY ASSAY AND INSTRUMENT ### I Background Information: A 510(k) Number K262807 B Applicant bioMérieux, Inc. C Proprietary and Established Names VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL); VITEK 2 AST-Gram Negative Imipenem (≤0.25 – ≥16 μg/mL); VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 – ≥16 μg/mL) D Regulatory Information | Product Code(s) | Classification | Regulation Section | Panel | | --- | --- | --- | --- | | LON | Class II | 21 CFR 866.1645 - Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System | MI - Microbiology | | LTT | Class II | 21 CFR 866.1640 - Antimicrobial susceptibility test powder | MI - Microbiology | | LTW | Class II | 21 CFR 866.1640 - Antimicrobial susceptibility test powder | MI - Microbiology | ### II Submission/Device Overview: A Purpose for Submission: This bundled submission seeks to: 1. Obtain a substantial equivalence determination as performed on the VITEK 2 Systems using an updated software version (v11.0) for: a. VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL), Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 www.fda.gov {2} b. VITEK 2 AST-Gram Negative Imipenem (≤0.25 – ≥16 μg/mL), and c. VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 – ≥16 μg/mL). 2. Reanalyze data to establish performance with updated FDA STIC-recognized breakpoints for polymyxin B. 3. Include the VITEK COMPACT PRO instrument for testing with VITEK 2 AST-Gram Negative Imipenem (≤0.25 – ≥16 μg/mL) and VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 – ≥16 μg/mL). # **B Measurand:** # **VITEK 2 AST-Gram Negative Polymyxin B:** Polymyxin B ≤0.25 – ≥16 μg/mL # **VITEK 2 AST-Gram Negative Imipenem:** Imipenem ≤0.25 – ≥16 μg/mL # **VITEK 2 AST-Gram Negative Ceftazidime/Avibactam:** Ceftazidime/Avibactam ≤0.125 – ≥16 μg/mL # **C Type of Test:** Automated quantitative or qualitative antimicrobial susceptibility test # **III Intended Use/Indications for Use:** # **A Intended Use(s):** See Indications for Use below. # **B Indication(s) for Use:** # **VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL):** VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL) is designed for antimicrobial susceptibility testing of Gram-negative bacilli and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of *in vitro* susceptibility to antimicrobial agents. VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL) is a quantitative test. Testing is indicated for *Acinetobacter* spp., Enterobacterales, and *Pseudomonas aeruginosa* as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL) has demonstrated acceptable performance with the following organism: *Pseudomonas aeruginosa* K262807 - Page 2 of 24 {3} The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic Gram negative bacilli to antimicrobial agents when used as instructed. ### VITEK 2 AST-Gram Negative Imipenem (≤0.25 – ≥16 μg/mL): VITEK 2 AST-Gram Negative Imipenem (≤0.25 – ≥16 μg/mL) is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK 2 Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 AST-Gram Negative Imipenem (≤0.25 – ≥16 μg/mL) is a quantitative test. Testing is indicated for Acinetobacter spp., Enterobacterales, and Pseudomonas aeruginosa as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). VITEK 2 AST-Gram Negative Imipenem (≤0.25 – ≥16 μg/mL) has demonstrated acceptable performance with the following organisms: Acinetobacter spp. (Acinetobacter baumannii, Acinetobacter baumannii complex) Enterobacterales (Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Enterobacter cloacae complex, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Klebsiella pneumoniae ssp. ozaenae, Klebsiella pneumoniae ssp. pneumoniae, Lelliottia amnigena, Pantoea despersa, Pseudescherichia vulneris, Raoultella ornithinolytica) Pseudomonas aeruginosa The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic Gram negative bacilli to antimicrobial agents when used as instructed. ### VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 – ≥16 μg/mL): VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 – ≥16 μg/mL) is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK 2 Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 – ≥16 μg/mL) is a quantitative test. Testing is indicated for Enterobacterales, and Pseudomonas aeruginosa as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 – ≥16 μg/mL) has demonstrated acceptable performance with the following organisms: Enterobacterales (Citrobacter freundii, Citrobacter koseri, Edwardsiella tarda, Enterobacter cloacae, Enterobacter cloacae ssp. cloacae, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Klebsiella pneumoniae ssp. pneumoniae, Morganella morganii, Morganella morganii ssp. morganii, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Serratia marcescens) Pseudomonas aeruginosa K262807 - Page 3 of 24 {4} The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic Gram negative bacilli to antimicrobial agents when used as instructed. ### C Special Conditions for Use Statement(s): Rx – For Prescription Use Only ### D Special Instrument Requirements: VITEK 2 Systems (i.e., VITEK 2, VITEK 2 Compact, and VITEK COMPACT PRO), Software version 11.0 or newer The ability of the AST card to detect resistant strains with the following combination(s) is unknown because an insufficient number of resistant strains were available at the time of comparative testing: Imipenem- Citrobacter freundii, Citrobacter koseri, Klebsiella oxytoca, Lelliottia amnigena, Pantoea dispersa, Pseudescherichia vulneris, Raoultella ornithinolytica Ceftazidime/Avibactam- Citrobacter koseri, Edwardsiella tarda, Klebsiella aerogenes, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescen ### IV Device/System Characteristics: ### A Device Description: The VITEK 2 AST card is a miniaturized, abbreviated and automated version of the doubling dilution technique for determining the minimum inhibitory concentration (MIC). Each VITEK 2 AST card contains 64 wells. A control well which contains only nutrient medium is resident on all cards. The remaining wells contain premeasured portions of antimicrobials combined with the nutrient media. The isolate to be tested is diluted to a standardized concentration with 0.45% to 0.50% saline before being used to rehydrate the antimicrobial medium within the card. VITEK 2 AST cards are intended to be used with VITEK 2 System instruments (VITEK 2, VITEK 2 Compact, and VITEK COMPACT PRO). The VITEK 2 System is a fully automated instrument that integrates sample preparation, incubation, and optical measurement for microbial identification and antimicrobial susceptibility testing (AST). The VITEK 2 System will automatically (or allow operator to manually) dilute the organism suspension to prepare an inoculum for susceptibility cards. Then, the VITEK 2 will fill, seal and place the card into the incubator/reader. The VITEK 2 Compact and VITEK COMPACT PRO have a manual filling, sealing, and loading operation. The VITEK 2 Systems monitor the growth of each well in the card over a defined period of time. The analysis program determines when a well demonstrates growth based on attenuation of light measured by an optical scanner. The data are used to determine the MIC values for the antimicrobial agent. At the completion of the K262807 - Page 4 of 24 {5} incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antimicrobial contained on the card. VITEK 2 AST-GN Polymyxin B has the following concentrations in the card: 0.125, 0.5, 2, and 8 µg/mL (equivalent standard method concentration by efficacy in µg/mL). The MIC result range for the VITEK 2 AST-GN Polymyxin B test is ≤0.25 - ≥16 µg/mL. VITEK 2 AST-GN Imipenem has the following concentrations in the card: 0.5, 2, 8, and 16 µg/mL (equivalent standard method concentration by efficacy in µg/mL). The MIC result range for the VITEK 2 AST-GN Imipenem test is ≤0.25 - ≥16 µg/mL. VITEK 2 AST-GN Ceftazidime/Avibactam has the following concentrations in the card: 0.06/4, 0.25/4, 1/4, 4/4, and 8/4 µg/mL (equivalent standard method concentration by efficacy in µg/mL). The MIC result range for the VITEK 2 AST-GN Ceftazidime/Avibactam test is ≤0.125 - ≥16 µg/mL. # **B Principle of Operation:** The VITEK 2 AST cards use an abbreviated doubling dilution series of antimicrobial to establish the MIC. Each VITEK 2 AST card contains 64 wells—one “growth” control well contains nutrient medium only, and the remaining wells contain premeasured antimicrobials in nutrient media. The VITEK 2 System instruments (VITEK 2, VITEK 2 Compact, and VITEK COMPACT PRO) utilize automated growth-based detection using attenuation of light measured by an optical scanner. The optics in the VITEK 2 Systems use visible light to directly measure organism growth within each of the 64 micro-wells. Transmittance optics is based on an initial light reading of a well before significant growth has begun. Every 15 minutes throughout the incubation cycle (defined period of time based on the VITEK 2 AST card), light transmittance readings of each well determine organism growth by the amount of light that is prevented from passing through the well. At the completion of the incubation period, the MIC values and their associated interpretive category results for each antimicrobial on the test card are displayed in an automatically generated report. # **C Instrument Description Information:** 1. Instrument Name: VITEK 2 System (VITEK 2, VITEK 2 Compact, and VITEK COMPACT PRO) 2. Specimen Identification: Patient information may be entered manually or downloaded from a data management system. The instrument reads the bar code information from the cards and cassettes and automatically sends the information to the system software. 3. Specimen Sampling and Handling: K262807 - Page 5 of 24 {6} Isolated colonies are inoculated into saline and manually or automatically adjusted to a 0.5 McFarland standard used to inoculate the susceptibility cards. The cards are then manually or automatically filled, sealed, and placed into the incubator/reader. # 4. Calibration: Self-calibrating # 5. Quality Control: Quality Control (QC) testing of the VITEK 2 System should be performed as dictated by the protocol in the package insert of each AST card and antimicrobial agent. The purpose of QC testing is to monitor performance of the VITEK 2 System as well as the proficiency of the laboratory personnel who use the system. The QC testing is performed with the manufacturer recommended QC strains. The QC workflow follows the same steps as the sample workflow. The QC results are generated and displayed on the user interface indicating the expected QC MIC range, the VITEK 2 System AST interpretive criteria call, and whether the relevant antimicrobial agents for the organism have passed or failed. # V Substantial Equivalence Information: # A Predicate Device Name(s): VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL) # B Predicate 510(k) Number(s): K193567 # C Comparison with Predicate(s): | Device & Predicate Device(s): | Devices K262807 | | | Predicate K193567 | | --- | --- | --- | --- | --- | | Device Trade Name | VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL) | VITEK 2 AST-Gram Negative Imipenem (≤0.25 – ≥16 μg/mL) | VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 – ≥16 μg/mL) | VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 – ≥16 μg/mL) | | **General Device Characteristic Similarities** | | | | | | Intended Use/Indications For Use | VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 - ≥16 μg/mL) is designed for antimicrobial susceptibility testing of Gram negative bacilli and are intended for use with the VITEK 2 and VITEK 2 Compact | VITEK 2 AST-Gram Negative Imipenem (≤0.25 - ≥16 μg/mL) is designed for antimicrobial susceptibility testing of Gram negative bacilli and are intended for use with the VITEK 2 Systems as a laboratory | VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 - ≥16 μg/mL) is designed for antimicrobial susceptibility testing of Gram negative bacilli and are intended for use with the VITEK 2 | VITEK 2 AST-Gram Negative Polymyxin B is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory | K262807 - Page 6 of 24 {7} | | Systems as a laboratory aid in the determination of *in vitro* susceptibility to antimicrobial agents. VITEK 2 AST-Gram Negative Polymyxin B (≤0.25 - ≥16 μg/mL) is a quantitative test. Testing is indicated for *Pseudomonas aeruginosa* as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems in clinical laboratories as an *in vitro* test to determine the susceptibility of clinically significant aerobic Gram negative bacilli to antimicrobial agents when used as instructed. | aid in the determination of *in vitro* susceptibility to antimicrobial agents. VITEK 2 AST-Gram Negative Imipenem (≤0.25 - ≥16 μg/mL) is a quantitative test. Testing is indicated for *Acinetobacter* spp., Enterobacterales, and *Pseudomonas aeruginosa* as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems in clinical laboratories as an *in vitro* test to determine the susceptibility of clinically significant aerobic Gram negative bacilli to antimicrobial agents when used as instructed. | Systems as a laboratory aid in the determination of *in vitro* susceptibility to antimicrobial agents. VITEK 2 AST-Gram Negative Ceftazidime/Avibactam (≤0.125 - ≥16 μg/mL) is a quantitative test. Testing is indicated for Enterobacterales and *Pseudomonas aeruginosa* as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems in clinical laboratories as an *in vitro* test to determine the susceptibility of clinically significant aerobic Gram negative bacilli to antimicrobial agents when used as instructed. | aid in the determination of *in vitro* susceptibility to antimicrobial agents. VITEK 2 AST-Gram Negative Polymyxin B is a quantitative test. Polymyxin B has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial. The VITEK 2 Gram-Negative Susceptibility Card is intended for use with the VITEK 2 Systems in clinical laboratories as an *in vitro* test to determine the susceptibility of clinically significant aerobic Gram-negative bacilli to antimicrobial agents when used as instructed. | | --- | --- | --- | --- | --- | | Test Methodology | Automated quantitative antimicrobial susceptibility test for use with the VITEK 2 Systems to determine the *in vitro* susceptibility of microorganisms | | | Same | | Inoculum | Saline suspension of organism | | | Same | | Test Card | Gram Negative (AST-GN) Susceptibility Test Card | | | Same | | Analysis Algorithm | Growth Pattern Analysis | | | Same | | **General Device Characteristic Differences** | | | | | | Antimicrobial Agent | Polymyxin B | Imipenem | Ceftazidime/Avibactam | Polymyxin B | | Antimicrobial Concentrations | 0.125, 0.5, 2, and 8 μg/mL | 0.5, 2, 8, and 16 μg/mL | 0.06/4, 0.25/4, 1/4, 4/4, and 8/4 μg/mL | 0.125, 0.5, 2, and 8 μg/mL | | Instrument | VITEK 2 and VITEK 2 Compact | VITEK 2, VITEK 2 Compact, and VITEK COMPACT PRO | | VITEK 2 and VITEK 2 Compact | | Knowledge Base | Knowledge Base threshold adjusted from 15% to 25% | | | Knowledge Base threshold set at 15% | | Tested/Reanalyzed Species | *Pseudomonas aeruginosa* | *Acinetobacter* spp. (*Acinetobacter baumannii*, | Enterobacterales (*Citrobacter freundii*, *Citrobacter koseri*, | *Pseudomonas aeruginosa* | K262807 - Page 7 of 24 {8} | | | Acinetobacter baumannii complex, Acinetobacter spp.) Enterobacterales (Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Enterobacter cloacae complex, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae ssp. ozaenae, Klebsiella pneumoniae ssp. pneumoniae, Klebsiella pneumoniae, Lelliottia amnigena, Pantoea despersa, Pseudescherichia vulneris, Raoultella ornithinolytica Pseudomonas aeruginosa | Edwardsiella tarda, Enterobacter cloacae, Enterobacter cloacae ssp. cloacae, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Klebsiella pneumoniae ssp. pneumoniae, Morganella morganii, Morganella morganii ssp. morganii, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Serratia marcescens Pseudomonas aeruginosa | | | --- | --- | --- | --- | --- | ### Predetermined Change Control Plan (PCCP): To support the implementation of changes to FDA-recognized susceptibility test interpretive criteria (i.e., breakpoints), this submission included a predetermined change control plan (PCCP) with a breakpoint change protocol that was reviewed and accepted by FDA in submission K250274 cleared on April 30, 2025. This protocol addresses future revisions to device labeling in response to breakpoint changes that are recognized on the FDA STIC webpage (FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria). The protocol outlined the specific procedures and acceptance criteria that bioMérieux, Inc. intends to use to evaluate the VITEK 2 AST-Gram Negative Polymyxin B, VITEK 2 AST-Gram Negative Imipenem, or VITEK 2 AST-Gram Negative Ceftazidime/Avibactam when revised breakpoints for polymyxin B, imipenem, or ceftazidime/avibactam are published on the FDA STIC webpage. The breakpoint change protocol included with the submission indicated that if specific criteria are met, bioMérieux, Inc. will update the VITEK 2 AST-Gram Negative Polymyxin B, VITEK 2 AST-Gram Negative Imipenem, or VITEK 2 AST-Gram Negative Ceftazidime/Avibactam label to include (1) the new breakpoints, (2) an updated performance section after re-evaluation of data in this premarket notification with the new breakpoints, and (3) any new limitations as determined by their evaluation. ### VI Standards/Guidance Documents Referenced: Guidance for Industry and FDA - Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems (Issued August 28, 2009) K262807 - Page 8 of 24 {9} CLSI M07 12th Edition, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically (May 2024) CLSI M100 35th Edition, Performance Standards for Antimicrobial Susceptibility Testing (January 2025) ### VII Performance Characteristics (if/when applicable): #### A Analytical Performance: 1. Precision/Reproducibility: The reproducibility of the VITEK 2 AST-Gram Negative Polymyxin B, VITEK 2 AST-Gram Negative Imipenem, and VITEK 2 AST-Gram Negative Ceftazidime/Avibactam was previously assessed in K193567, K183415, and K172944, respectively. Refer to K193567, K183415, and K172944 Decision Summaries for additional details. 2. Linearity: Not applicable. 3. Analytical Specificity/Interference: Not applicable. 4. Detection Limit and Assay Reportable Range: Not applicable. 5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): **Quality Control (QC) Testing:** The QC performance using CLSI recommended QC strains for the VITEK 2 AST-Gram Negative Polymyxin B, VITEK 2 AST-Gram Negative Imipenem, and VITEK 2 AST-Gram Negative Ceftazidime/Avibactam was previously assessed in K193567, K183415, and K172944, respectively. Refer to K193567, K183415, and K172944 Decision Summaries for additional details. 6. Assay Cut-Off: Not applicable. #### B Comparison Studies: 1. Method Comparison with Predicate Device: K262807 - Page 9 of 24 {10} ## VITEK AST-Gram Negative Polymyxin B Results from testing of polymyxin B on the VITEK 2 AST-Gram Negative card was previously submitted and reviewed in K193567 (refer to K193657 Decision Summary). Following the VITEK 2 AST-GN knowledge base analysis modification, the original clinical and challenge data from K193567 were reanalyzed using the updated VITEK 2 System software version. In addition, the FDA STIC-recognized breakpoints for polymyxin B have been updated since K193567 clearance and the reanalysis was performed using the updated breakpoints and the updated software. Data from 277 P. aeruginosa clinical isolates evaluated with the auto-dilution method (VITEK 2) was reanalyzed. Additionally, data from 85 P. aeruginosa challenge isolates evaluated with the auto-dilution method (VITEK 2) and the manual dilution method (VITEK 2, VITEK 2 Compact) were also reanalyzed. Reanalyzed results are summarized in Tables 1 and 2. ### Clinical and Challenge Data – VITEK 2 Auto-Dilution Table 1. Reanalyzed Performance of All Clinical and Challenge Isolates for Polymyxin B: VITEK 2 Auto-Dilution | | Total | #EA | %EA | Eval EA Total | Eval EA # | Eval EA % | #CA | %CA | #R | #I | min | maj | vmj | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Pseudomonas aeruginosa ≤2 (I), ≥4 (R) | | | | | | | | | | | | | | | Clinical | 277 | 263 | 95.0 | 272 | 258 | 94.9 | 266 | 96.0 | 9 | 268 | n/a | 3 | 8 | | Challenge | 85 | 80 | 94.1 | 81 | 76 | 93.8 | 85 | 100 | 8 | 77 | n/a | 0 | 0 | | Combined | 362 | 343 | 94.8 | 353 | 334 | 94.6 | 351 | 97.0 | 17 | 345 | n/a | 3 | 8 | EA – Essential Agreement CA – Category Agreement Eval – Evaluable isolates R- Resistant n/a – Not Applicable min – Minor Discrepancies maj – Major Discrepancies vmj – Very Major Discrepancies I – Intermediate Essential agreement (EA) occurs when the result of the reference method and that of the VITEK 2 AST card are within plus or minus one serial two-fold dilution of the antibiotic. Evaluable results are those that are on-scale for both the reference method and VITEK 2 AST card or results in which an off-scale result is at least two doubling dilutions from the on-scale result. Category agreement occurs when the interpretation of the result of the reference method agrees exactly with the interpretation of the VITEK 2 AST card. For P. aeruginosa evaluated with the auto-dilution method of the VITEK 2, the reanalyzed EA was acceptable at 94.8% (Table 1). The reanalyzed CA was acceptable at 97.0% and there were three potential major errors and eight potential very major errors. This is a unique case where there is not a defined susceptible (S) interpretive category for polymyxin B; therefore, the intermediate (I) category is treated as an S for performance analysis. In these situations, where errors cannot be categorized as minor, adjustments are made to categorical errors by considering if the MIC values where the errors occur are in essential agreement with the reference method. Additionally, due to the lack of a susceptible interpretive category, all errors are considered potential errors. Two of the three potential major errors were in essential agreement; therefore, the adjusted potential major error rate is 0.3% (1/345), which K262807 - Page 10 of 24 {11} is acceptable. One of the eight potential very major errors had an MIC value that was in essential agreement with the reference method MIC value; therefore, the adjusted potential very major error rate is 41.2% (7/17). When there is not a defined susceptible interpretive category and the intermediate category is considered as susceptible for performance analysis, the adjusted potential errors are evaluated in the context of the extent of testing and the current guidelines for testing and reporting of results for this antimicrobial. In this case, the robust testing of a single organism reporting group included a high number of isolates with on-scale results and demonstrated a high EA, a very good EA of the evaluable results, and high CA. The following footnote is included in the device labeling to address the high adjusted potential very major error rate: **IMPORTANT:** There is not a defined “S” category for Polymyxin B, as the available clinical and pharmacokinetic and pharmacodynamic (PK/PD) data does not support defining an MIC that can reliably predict clinical efficacy. Refer to applicable clinical and laboratory guidelines for testing and reporting considerations, including CLSI M100 which outlines the following Warning for Polymyxin B. **WARNING:** Clinical and PK/PD data demonstrate...Polymyxin B ha(s) limited clinical efficacy, even if an intermediate result is obtained. Alternate agents are strongly preferred... Polymyxin B should be used in combination with 1 or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended. As Polymyxin B does not have a Susceptible (S) breakpoint, the Intermediate (I) category was treated as an (S) to evaluate performance. As such, all categorical errors between Intermediate (I) and Resistant (R) were counted as either potential Major or potential Very Major errors instead of minor errors (mE). When testing Polymyxin B with Pseudomonas aeruginosa, there were eight (8) potential Very Major errors (47.1%) (i.e. VITEK 2 result was Intermediate (I) and the reference method was resistant (R)). Of the 8 potential Very Major errors for Polymyxin B, one (1) result was within Essential Agreement (EA) of the reference method. With adjustments made for MICs that are in EA with the reference method, the adjusted potential Very Major error rate for Polymyxin B when testing Pseudomonas aeruginosa with the VITEK 2 system was 41.2% (with 7/17 Very Major errors being two doubling dilutions lower than the reference method). ### Challenge Data –VITEK 2 and VITEK 2 Compact Manual Dilution Table 2. Reanalyzed Performance of Challenge Isolates for Polymyxin B: VITEK 2 and VITEK 2 Compact Manual Dilution | VITEK 2 Systems | Total | #EA | %EA | Eval Total | Eval EA # | Eval EA % | #CA | %CA | #R | #I | min | maj | vmj | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | *Pseudomonas aeruginosa* ≤2 (I), ≥4 (R) | | | | | | | | | | | | | | | VITEK 2 | 85 | 82 | 96.5 | 79 | 76 | 96.2 | 85 | 100 | 8 | 77 | n/a | 0 | 0 | K262807 - Page 11 of 24 {12} | VITEK 2 Compact | 85 | 83 | 97.7 | 80 | 78 | 97.5 | 85 | 100 | 8 | 77 | n/a | 0 | 0 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | EA – Essential Agreement min – Minor Discrepancies CA – Category Agreement maj – Major Discrepancies Eval – Evaluable isolates vmj – Very Major Discrepancies R– Resistant I – Intermediate n/a – Not Applicable Essential agreement (EA) occurs when the result of the reference method and that of the VITEK 2 AST card are within plus or minus one serial two-fold dilution of the antibiotic. Evaluable results are those that are on-scale for both the reference method and VITEK 2 AST card or results in which an off-scale result is at least two doubling dilutions from the on-scale result. Category agreement occurs when the interpretation of the result of the reference method agrees exactly with the interpretation of the VITEK 2 AST card. The reanalyzed performance of the VITEK 2 AST-Gram Negative Polymyxin B when testing P. aeruginosa with the manual dilution method of the VITEK 2 is acceptable with an EA of 96.5%, a CA of 100%, and no potential major or very major errors. The performance of the VITEK 2 AST-Gram Negative Polymyxin B when testing P. aeruginosa with the VITEK 2 Compact is acceptable with an EA of 97.7%, a CA of 100%, and no potential major or very major errors. ### VITEK AST-Gram Negative Imipenem Results from testing of imipenem on the VITEK 2 AST-Gram Negative card was previously submitted and reviewed in K183415 (refer to K183415 Decision Summary). Following the VITEK 2 AST-GN knowledge base analysis modification, the original clinical and challenge data were reanalyzed using the updated VITEK 2 System software version. Data from 383 clinical isolates including 34 Acinetobacter spp. (20 A. baumannii, 11 A. baumannii complex, 3 Acinetobacter spp. not differentiated), 277 Enterobacterales (1 C. braakii, 7 C. freundii, 5 C. koseri, 10 E. cloacae, 22 E. cloacae complex, 97 E. coli, 23 K. oxytoca, 52 K. pneumoniae, 4 K. pneumoniae ssp. pneumoniae, 1 L. amnigena, 2 P. dispersa, 2 P. vulneris, 1 R. ornithinolytica), and 122 Pseudomonas aeruginosa were evaluated with the auto-dilution method (VITEK 2) were reanalyzed. Reanalyzed results are summarized in Table 3. Additionally, data from 217 challenge isolates including 23 Acinetobacter spp. (9 A. baumannii, 14 A. baumannii complex), 139 Enterobacterales (1 C. freundii, 15 E. cloacae, 3 E. cloacae complex, 6 E. coli, 1 K. oxytoca, 96 K. pneumoniae, 1 K. pneumoniae ssp. ozaenae, 16 K. pneumoniae ssp. pneumoniae), and 55 Pseudomonas aeruginosa evaluated with the auto-dilution method (VITEK 2) and the manual dilution method (VITEK 2, VITEK 2 Compact were also reanalyzed. Reanalyzed results are summarized in Tables 3 and 4. ### Clinical and Challenge Data – VITEK 2 Auto-Dilution Table 3. Reanalyzed Performance of All Clinical and Challenge Isolates for Imipenem: VITEK 2 Auto-Dilution | | Total | #EA | %EA | Eval EA Total | Eval EA # | Eval EA % | #CA | %CA | #R | #S | min | maj | vmj | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Acinetobacter spp. ≤2 (S), 4 (I), ≥8 (R) | | | | | | | | | | | | | | K262807 - Page 12 of 24 {13} | Clinical | 34 | 34 | 100 | 1 | 1 | 100 | 34 | 100 | 19 | 15 | 0 | 0 | 0 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Challenge | 23 | 22 | 95.7 | 5 | 4 | 80 | 22 | 95.7 | 20 | 3 | 1 | 0 | 0 | | Combined | 57 | 56 | 98.2 | 6 | 5 | 88.3 | 56 | 98.2 | 39 | 18 | 1 | 0 | 0 | Enterobacterales ≤1 (S), 2 (I), ≥4 (R) | Clinical | 227 | 213 | 93.8 | 45 | 31 | 68.9 | 217 | 95.6 | 8 | 212 | 10 | 0 | 0 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Challenge | 139 | 136 | 97.8 | 30 | 27 | 90.0 | 136 | 97.8 | 120 | 18 | 3 | 0 | 0 | | Combined | 366 | 349 | 95.4 | 75 | 58 | 77.3 | 353 | 96.4 | 128 | 230 | 13 | 0 | 0 | Pseudomonas aeruginosa ≤2 (S), 4 (I), ≥8 (R) | Clinical | 122 | 115 | 94.3 | 71 | 64 | 90.1 | 111 | 91.0 | 61 | 51 | 9 | 0 | 2 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Challenge | 55 | 53 | 96.4 | 24 | 22 | 91.7 | 51 | 92.7 | 39 | 15 | 4 | 0 | 0 | | Combined | 177 | 168 | 94.9 | 95 | 86 | 90.5 | 162 | 91.5 | 100 | 66 | 13 | 0 | 2 | EA – Essential Agreement min – Minor Discrepancies CA – Category Agreement maj – Major Discrepancies Eval – Evaluable isolates vmj – Very Major Discrepancies R – Resistant S – Susceptible Essential agreement (EA) occurs when the result of the reference method and that of the VITEK 2 AST card are within plus or minus one serial two-fold dilution of the antibiotic. Evaluable results are those that are on-scale for both the reference method and VITEK 2 AST card or results in which an off-scale result is at least two doubling dilutions from the on-scale result. Category agreement occurs when the interpretation of the result of the reference method agrees exactly with the interpretation of the VITEK 2 AST card. The overall reanalyzed performance of the VITEK 2 AST-Gram Negative Imipenem when testing Acinetobacter spp. with the auto-dilution method of the VITEK 2 is acceptable with an EA of 95.1%, a CA of 98.2%, one minor error, and no major or very major errors (Table 3). The overall reanalyzed performance of the VITEK 2 AST-Gram Negative Imipenem when testing Enterobacterales with the auto-dilution method of the VITEK 2 is acceptable with an EA of 95.4%, a CA of 96.4%, thirteen (13) minor errors, and no major or very major errors (Table 3). The reanalyzed performance of the VITEK 2 AST-Gram Negative Imipenem when testing P. aeruginosa with the auto-dilution method of the VITEK 2 is acceptable with an EA of 94.9%, a CA of 91.5%, thirteen (13) minor errors, no major errors, and two very major errors (2/100 = 2.0%) (Table 3). ### Challenge Data –VITEK 2 and VITEK 2 Compact Manual Dilution Table 4. Reanalyzed Performance of Challenge Isolates for Imipenem: VITEK 2 and VITEK 2 Compact Manual Dilution | VITEK 2 Systems | Total | #EA | %EA | Eval Total | Eval EA # | Eval EA % | #CA | %CA | #R | #S | min | maj | vmj | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Acinetobacter spp. ≤2 (S), 4 (I), ≥8 (R) | | | | | | | | | | | | | | K262807 - Page 13 of 24 {14} | VITEK 2 | 23 | 22 | 95.7 | 5 | 4 | 80.0 | 22 | 96.7 | 20 | 3 | 1 | 0 | 0 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | VITEK 2 Compact | 23 | 22 | 95.7 | 5 | 4 | 80.0 | 22 | 95.7 | 20 | 3 | 1 | 0 | 0 | | Enterobacterales ≤1 (S), 2 (I), ≥4 (R) | | | | | | | | | | | | | | | VITEK 2 | 139 | 137 | 98.6 | 29 | 27 | 93.1 | 133 | 95.7 | 120 | 18 | 6 | 0 | 0 | | VITEK 2 Compact | 139 | 136 | 97.8 | 30 | 27 | 90.0 | 136 | 97.8 | 120 | 18 | 3 | 0 | 0 | | Pseudomonas aeruginosa ≤2 (S), 4 (I), ≥8 (R) | | | | | | | | | | | | | | | VITEK 2 | 55 | 53 | 96.4 | 23 | 21 | 91.3 | 50 | 90.9 | 39 | 15 | 5 | 0 | 0 | | VITEK 2 Compact | 55 | 53 | 96.4 | 22 | 20 | 90.9 | 51 | 92.7 | 39 | 15 | 4 | 0 | 0 | EA – Essential Agreement CA – Category Agreement Eval – Evaluable isolates R – Resistant min – Minor Discrepancies maj – Major Discrepancies vmj – Very Major Discrepancies S – Susceptible Essential agreement (EA) occurs when the result of the reference method and that of the VITEK 2 AST card are within plus or minus one serial two-fold dilution of the antibiotic. Evaluable results are those that are on-scale for both the reference method and VITEK 2 AST card or results in which an off-scale result is at least two doubling dilutions from the on-scale result. Category agreement occurs when the interpretation of the result of the reference method agrees exactly with the interpretation of the VITEK 2 AST card. The overall reanalyzed performance of the VITEK 2 AST-Gram Negative Imipenem when testing Acinetobacter spp. with the manual dilution method of the VITEK 2 is acceptable with an EA of 95.7%, a CA of 96.7%, one minor error, and no major or very major errors. The overall performance of the VITEK 2 AST-Gram Negative Imipenem when testing Acinetobacter spp. with the VITEK 2 Compact is acceptable with an EA of 95.7%, a CA of 95.7%, one minor error, and no major or very major errors. The overall reanalyzed performance of the VITEK 2 AST-Gram Negative Imipenem when testing Enterobacterales with the manual dilution method of the VITEK 2 is acceptable with an EA of 98.6%, a CA of 90.9%, six minor errors, and no major or very major errors. The overall performance of the VITEK 2 AST-Gram Negative Imipenem when testing Enterobacterales with the VITEK 2 Compact is acceptable with an EA of 97.8%, a CA of 97.8%, three minor errors, and no major or very major errors. The reanalyzed performance of the VITEK 2 AST-Gram Negative Imipenem when testing P. aeruginosa with the manual dilution method of the VITEK 2 is acceptable with an EA of 96.4%, a CA of 95.7%, five minor errors, and no major or very major errors. The performance of the VITEK 2 AST-Gram Negative Imipenem when testing P. aeruginosa with the VITEK 2 Compact is acceptable with an EA of 96.4%, a CA of 92.7%, four minor errors, and no major or very major errors. Due to the insufficient number of resistant isolates evaluated, the following limitation is included in the device labeling: The ability of the AST card to detect resistant strains with the following combination(s) is unknown because an insufficient number of resistant strains were available at the time of comparative testing: K262807 - Page 14 of 24 {15} Citrobacter freundii, Citrobacter koseri, Klebsiella oxytoca, Lelliottia amnigena, Pantoea dispersa, Pseudescherichia vulneris, Raoultella ornithinolytica ## VITEK AST-Gram Negative Ceftazidime-Avibactam Results from testing of ceftazidime/avibactam on the VITEK 2 AST-Gram Negative card was previously submitted and reviewed in K172944 (refer to K172944 Decision Summary). Following the VITEK 2 AST-GN knowledge base analysis modification, the original clinical and challenge data were reanalyzed using the updated VITEK 2 System software version. Data from 952 clinical isolates including 791 Enterobacterales (51 C. freundii, 43 C. koseri, 1 Edwardsiella tarda, 34 E. cloacae, 19 E. cloacae complex, 24 E. cloacae ssp. cloacae, 159 E. coli, 46 K. aerogenes, 44 K. oxytoca, 55 K. pneumoniae, 96 K. pneumoniae ssp. pneumoniae, 12 M. morganii, 18 M. morganii ssp. morganii, 59 P. mirabilis, 29 P. vulgaris, 24 P. stuartii, 77 S. marcescens) and 161 Pseudomonas aeruginosa were evaluated with the auto-dilution method (VITEK 2) were reanalyzed. Reanalyzed results are summarized in Tables 5 and 6. Data from 93 challenge isolates including 47 Enterobacterales (5 C. freundii, 9 E. cloacae, 10 E. coli, 1 K. aerogenes, 4 K. oxytoca, 10 K. pneumoniae, 6 K. pneumoniae ssp. pneumoniae, 1 P. stuartii, 1 S. marcescens) and 46 Pseudomonas aeruginosa evaluated with the auto-dilution method (VITEK 2) and the manual dilution method (VITEK 2, VITEK 2 Compact) were also reanalyzed. Reanalyzed results are summarized in Tables 5 and 6. ## Clinical and Challenge Data – VITEK 2 Auto-Dilution Table 5. Reanalyzed Performance of All Clinical and Challenge Isolates for Ceftazidime/Avibactam: VITEK 2 Auto-Dilution | | Total | #EA | %EA | Eval EA Total | Eval EA # | Eval EA % | #CA | %CA | #R | #S | min | maj | vmj | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Enterobacterales ≤8/4 (S), - (I), ≥16/4 (R) | | | | | | | | | | | | | | | Clinical | 791 | 752 | 95.1 | 238 | 199 | 83.6 | 788 | 99.6 | 9 | 782 | n/a | 3 | 0 | | Challenge | 47 | 45 | 95.7 | 20 | 18 | 90.0 | 46 | 97.9 | 27 | 20 | n/a | 1 | 0 | | Combined | 838 | 797 | 95.1 | 258 | 217 | 84.1 | 834 | 99.5 | 36 | 802 | n/a | 4 | 0 | | Pseudomonas aeruginosa ≤8/4 (S), - (I), ≥16/4 (R) | | | | | | | | | | | | | | | Clinical | 161 | 152 | 94.4 | 145 | 136 | 93.8 | 154 | 95.7 | 10 | 151 | n/a | 7 | 0 | | Challenge | 46 | 46 | 100 | 18 | 18 | 100 | 46 | 100 | 28 | 18 | n/a | 0 | 0 | | Combined | 207 | 198 | 95.7 | 163 | 154 | 94.5 | 200 | 96.6 | 38 | 169 | n/a | 7 | 0 | EA – Essential Agreement CA – Category Agreement Eval – Evaluable isolates R – Resistant n/a – Not Applicable min – Minor Discrepancies maj – Major Discrepancies vmj – Very Major Discrepancies S – Susceptible K262807 - Page 15 of 24 {16} Essential agreement (EA) occurs when the result of the reference method and that of the VITEK 2 AST card are within plus or minus one serial two-fold dilution of the antibiotic. Evaluable results are those that are on-scale for both the reference method and VITEK 2 AST card or results in which an off-scale result is at least two doubling dilutions from the on-scale result. Category agreement occurs when the interpretation of the result of the reference method agrees exactly with the interpretation of the VITEK 2 AST card. The overall reanalyzed performance of the VITEK 2 AST-Gram Negative Ceftazidime/Avibactam when testing Enterobacterales with the auto-dilution method of the VITEK 2 was acceptable with an EA of 95.1%, a CA of 99.5%, four major errors (4/802 = 0.5%), and no very major errors (Table 5). Due to the lack of an intermediate interpretive criteria for ceftazidime/avibactam, where errors cannot be categorized as minor, adjustments are made to categorical errors by considering if the MIC values where the errors occur are in essential agreement with the reference method. Three of the four major errors had MIC values that were in essential agreement with the reference method MIC value; therefore, the adjusted very major error rate is 0.1% (1/802). Performance was acceptable. The reanalyzed performance of the VITEK 2 AST-Gram Negative Ceftazidime/Avibactam when testing P. aeruginosa with the auto-dilution method of the VITEK 2 was acceptable with an EA of 95.7% and a CA of 96.6%. There were seven (7) major errors (7/169 = 4.1%) and no very major errors. Five of the seven major errors had MIC values that were in essential agreement with the reference method MIC value; therefore, the adjusted major error rate is 1.2% (2/169), which is acceptable. Based on the reanalyzed performance of VITEK 2 AST-Gram Negative Ceftazidime-Avibactam using the auto-dilution method of the VITEK 2, the following footnotes and limitations have been removed from device labeling: The overall categorical major error rate for Enterobacteriaceae and Pseudomonas aeruginosa combined was 1.4% (14/998). Nine (9) major errors were one dilution apart from the reference method and as such fall within essential agreement. Based on the essential agreement, and the lack of an intermediate breakpoint for Ceftazidime/Avibactam, the adjusted categorical major error rate is 0.5% (5/998). Although within Essential Agreement when compared to the reference method, errors (major and/or very major) were observed due to the lack of intermediate category. Testing should be repeated using an alternative testing/reference method prior to reporting results for the following antibiotic/organism(s): - Ceftazidime/Avibactam (cza02n): Pseudomonas aeruginosa when the VITEK 2 MIC is ≥ 16 μg/mL due to observed major errors (4.1%), with an adjusted categorical major error rate of 1.2%. ### Challenge Data –VITEK 2 and VITEK 2 Compact Manual Dilution K262807 - Page 16 of 24 {17} Table 6. Reanalyzed Performance of Challenge Isolates for Ceftazidime/Avibactam: VITEK 2 and VITEK 2 Compact Manual Dilution | VITEK 2 Systems | Total | #EA | %EA | Eval Total | Eval EA # | Eval EA % | #CA | %CA | #R | #S | min | maj | vmj | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Enterobacterales ≤8/4 (S), - (I), ≥16/4 (R) | | | | | | | | | | | | | | | VITEK 2 | 47 | 46 | 97.9 | 19 | 18 | 94.7 | 46 | 97.9 | 27 | 20 | n/a | 1 | 0 | | VITEK 2 Compact | 47 | 46 | 97.9 | 19 | 18 | 94.7 | 46 | 97.9 | 27 | 20 | n/a | 1 | 0 | | Pseudomonas aeruginosa ≤8/4 (S), - (I), ≥16/4 (R) | | | | | | | | | | | | | | | VITEK 2 | 46 | 46 | 100 | 18 | 18 | 100 | 46 | 100 | 28 | 18 | n/a | 0 | 0 | | VITEK 2 Compact | 46 | 46 | 100 | 18 | 18 | 100 | 46 | 100 | 28 | 18 | n/a | 0 | 0 | EA – Essential Agreement min – Minor Discrepancies CA – Category Agreement maj – Major Discrepancies Eval – Evaluable isolates vmj – Very Major Discrepancies R – Resistant S – Susceptible n/a – Not Applicable Essential agreement (EA) occurs when the result of the reference method and that of the VITEK 2 AST card are within plus or minus one serial two-fold dilution of the antibiotic. Evaluable results are those that are on-scale for both the reference method and VITEK 2 AST card or results in which an off-scale result is at least two doubling dilutions from the on-scale result. Category agreement occurs when the interpretation of the result of the reference method agrees exactly with the interpretation of the VITEK 2 AST card. The overall reanalyzed performance of the VITEK 2 AST-Gram Negative Ceftazidime/Avibactam when testing Enterobacterales with the manual dilution method of the VITEK 2 had an EA of 97.9%, a CA of 97.9%, one major error (1/20 = 5%), and no very major errors. The one major error was not in essential agreement with the reference method; therefore, the adjusted major error rate is 5% (1/20). The overall performance of the VITEK 2 AST-Gram Negative Ceftazidime/ Avibactam when testing Enterobacterales with the VITEK 2 Compact is acceptable with an EA of 97.9%, a CA of 97.9%, one major error (1/20 = 5%), and no very major errors. When evaluating by individual species, the one adjusted major error for both manual methods was due to a K. aerogenes isolate (1/1 = 100%). Due to the lack of susceptible isolates evaluated, the major error is considered random, and performance is acceptable. The reanalyzed performance of the VITEK 2 AST-Gram Negative Ceftazidime/Avibactam when testing P. aeruginosa with the manual dilution method of the VITEK 2 is acceptable with an EA of 100%, a CA of 100%, and no major or very major errors. The performance of the VITEK 2 AST-Gram Negative Ceftazidime/Avibactam when testing P. aeruginosa with the VITEK 2 Compact is acceptable with an EA of 100%, a CA of 100%, and no major or very major errors. Due to the insufficient number of resistant isolates evaluated, the following limitation is included in the device labeling: The ability of the AST card to detect resistant strains with the following combination(s) is unknown because an insufficient number of resistant strains were available at the time of comparative testing: K262807 - Page 17 of 24 {18} Citrobacter koseri, Edwardsiella tarda, Klebsiella aerogenes, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens ## MIC Trending Following the VITEK 2 AST-GN knowledge base analysis modification, a trending analysis was conducted using the combined data (clinical and/or challenge) obtained for the reanalysis of: - Polymyxin B- Pseudomonas aeruginosa (Table 7) - Imipenem- Acinetobacter spp., Enterobacterales, Pseudomonas aeruginosa (Table 8) - Ceftazidime/avibactam- Enterobacterales, Pseudomonas aeruginosa (Table 9) This trending calculation takes into account MIC values that are determined to be one or more doubling dilutions lower or higher than the reference method irrespective of whether the device MIC values are on-scale or not. Species for which the difference between the percentage of isolates with higher vs. lower readings was > 30% and for which the confidence interval was determined to be statistically significant were considered to show evidence of trending. Trending that shows higher or lower MIC values compared to the reference is addressed in the labeling., ## MIC Trending- VITEK 2 AST-Gram Negative Polymyxin B Table 7. Trending for P. aeruginosa with Polymyxin B and the VITEK 2 Systems | Organism | Inoculation/ Read Method | Total Evaluable for Trending | ≥ 1 Dilution lower No. (%) | Exact No. (%) | ≥ 1 Dilution Higher No. (%) | Percent Difference (CI) | Trending Noted | | --- | --- | --- | --- | --- | --- | --- | --- | | P. aeruginosa | Auto/ VITEK 2 | 356 | 90, (22.3) | 186 | 80, (22.5) | -3% (-9%, 3%) | No | | | Manual/ VITEK 2 | 80 | 8, (10.0) | 42 | 30, (37.5) | 28% (15%, 39%) | No | | | Manual/ VITEK 2 Compact | 81 | 10, (21.4) | 41 | 30, (37.0) | 25% (12%, 37%) | No | ## MIC Trending- VITEK 2 AST-Gram Negative Imipenem Table 8. Trending for Acinetobacter spp., Enterobacterales, and P. aeruginosa with Imipenem and the VITEK 2 Systems | Organism | Inoculation/ Read Method | Total Evaluable for Trending | ≥ 1 Dilution lower No. (%) | Exact No. (%) | ≥ 1 Dilution Higher No. (%) | Percent Difference (CI) | Trending Noted | | --- | --- | --- | --- | --- | --- | --- | --- | | A. baumannii | Auto/ VITEK 2 | 4 | 0, (0.0) | 4 | 0, (0.0) | 0% (-49%, 49%) | No | | | Manual/ VITEK 2 | 3 | 0, (0.0) | 2 | 1, (33.3) | 33% (-29%, 79%) | No | K262807 - Page 18 of 24 {19} | | Manual/VITEK 2 Compact | 3 | 0, (0.0) | 2 | 1, (33.3) | 33% (-29%, 79%) | No | | --- | --- | --- | --- | --- | --- | --- | --- | | A. baumannii complex | Auto/VITEK 2 | 2 | 1, (50.0) | 1 | 0, (0.0) | -50% (-91%, 27%) | n/a | | | Manual/VITEK 2 | 2 | 1, (50.0) | 0 | 1, (50.0) | 0% (-57%, 57%) | n/a | | | Manual/VITEK 2 Compact | 2 | 1, (50.0) | 1 | 0, (0.0) | -50% (-91%, 27%) | n/a | | C. freundii | Auto/VITEK 2 | 7 | 2, (28.6) | 4 | 1, (14.3) | -14% (-52%, 28%) | No | | | Manual/VITEK 2 | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | | Manual/VITEK 2 Compact | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | C. koseri | Auto/VITEK 2 | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | E. cloacae | Auto/VITEK 2 | 22 | 5, (22.7) | 10 | 7, (31.8) | 9% (-17%, 33%) | No | | | Manual/VITEK 2 | 13 | 0, (0.0) | 5 | 8, (61.5) | 62% (27%, 82%) | Yes | | | Manual/VITEK 2 Compact | 13 | 0, (0.0) | 8 | 5, (38.5) | 38% (8%, 64%) | Yes | | E. cloacae complex | Auto/VITEK 2 | 20 | 4, (20.0) | 7 | 9, (45.0) | 25% (-4%, 49%) | No | | | Manual/VITEK 2 | 1 | 1, (100) | 0 | 0, (0.0) | -100% (-100%, 12%) | n/a | | | Manual/VITEK 2 Compact | 1 | 0, (0.0) | 1 | 1, (100) | -100% (-100%, 12%) | n/a | | E. coli | Auto/VITEK 2 | 12 | 6, (50.0) | 0 | 6, (50.0) | 0% (-35%, 35%) | No | | | Manual/VITEK 2 | 5 | 2, (40.0) | 2 | 1, (20.0) | 20% (-60%, 31%) | No | | | Manual/VITEK 2 Compact | 5 | 2, (40.0) | 0 | 3, (60.0) | 20% (-32%, 60%) | No | | K. oxytoca | Auto/VITEK 2 | 6 | 5, (83.3) | 1 | 0, (0.0) | -83% (-97%, -28%) | Yes | | | Manual/VITEK 2 | 1 | 0, (0.0) | 1 | 0, (0.0) | 0% (-79%, 79%) | n/a | | | Manual/VITEK 2 Compact | 1 | 0, (0.0) | 1 | 0, (0.0) | 0% (-79%, 79%) | n/a | K262807 - Page 19 of 24 {20} | K. pneumoniae | Auto/VITEK 2 | 49 | 29, (59.2) | 5 | 15, (30.6) | -29%(-45%, -9%) | No | | --- | --- | --- | --- | --- | --- | --- | --- | | | Manual/VITEK 2 | 26 | 9, (34.6) | 3 | 14, (53.9) | 19%(-7%, 42%) | No | | | Manual/VITEK 2Compact | 26 | 5, (19.2) | 4 | 17, (65.4) | 46%(19%, 65%) | Yes | | K. pneumoniaessp. ozaenae | Auto/VITEK 2 | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | | Manual/VITEK 2 | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | | Manual/VITEK 2Compact | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | K. pneumoniaesssp. pneumoniae | Auto/VITEK 2 | 9 | 5, (55.6) | 1 | 3, (33.3) | -22%(-55%, 20%) | No | | | Manual/VITEK 2 | 6 | 2, (33.3) | 1 | 3, (50.0) | 17%(-32%, 56%) | No | | | Manual/VITEK 2Compact | 7 | 2, 28.6) | 1 | 4, (57.1) | 29%(-19%, 62%) | No | | L. amnigena | Auto/VITEK 2 | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | P. dispersa | Auto/VITEK 2 | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | P. vulneris | Auto/VITEK 2 | 1 | 1, (100) | 0 | 0, (0.0) | -100%(100%, 12%) | n/a | | R. ornithinloytica | Auto/VITEK 2 | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | P. aeruginosa | Auto/VITEK 2 | 96 | 32, (33.3) | 37 | 27, (28.1) | -5%(-18%, 8%) | No | | | Manual/VITEK 2 | 23 | 8, (34.8) | 9 | 6, (26.1) | -9%(-33%, 17%) | No | | | Manual/VITEK 2Compact | 22 | 7, (31.8) | 10 | 5, (22.7) | -9%(-33%, 17%) | No | A trend toward higher MIC values was observed for E. cloacae and K. pneumoniae when compared to the CLSI broth microdilution reference method, as summarized in Table 8. A trend toward lower MIC values was observed for K. oxytoca when compared to the CLSI broth microdilution reference method, as summarized in Table 8. The following statement is included as a footnote to the performance table in the device labeling to address the observed trending: K262807 - Page 20 of 24 {21} VITEK 2 AST-Gram Negative Imipenem MIC values tended to be in exact agreement or at least one doubling dilution higher when testing Enterobacter cloacae and Klebsiella pneumoniae, and at least one dilution lower when testing Klebsiella oxytoca as compared to the CLSI reference broth microdilution method. ## MIC Trending- VITEK 2 AST-Gram Negative Ceftazidime/Avibactam Table 9. Trending for Enterobacterales and P. aeruginosa with Ceftazidime/Avibactam and the VITEK 2 Systems | Organism | Inoculation/Read Method | Total Evaluable for Trending | ≥ 1 Dilution lower No. (%) | Exact No. (%) | ≥ 1 Dilution Higher No. (%) | Percent Difference (CI) | Trending Noted | | --- | --- | --- | --- | --- | --- | --- | --- | | C. freundii | Auto/VITEK 2 | 26 | 6, (23.1) | 7 | 13, (50.0) | 27% (1%, 49%) | No | | | Manual/VITEK 2 | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | | Manual/VITEK 2 Compact | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | C. koseri | Auto/VITEK 2 | 6 | 1, (16.7) | 0 | 5, (83.3) | 67% (11%, 86%) | Yes | | E. tarda | Auto/VITEK 2 | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | E. cloacae | Auto/VITEK 2 | 32 | 3, (9.4) | 17 | 12, (37.5) | 28% (7%, 46%) | No | | | Manual/VITEK 2 | 2 | 0, (0.0) | 0 | 2, (100) | 100% (7%, 100%) | n/a | | | Manual/VITEK 2 Compact | 2 | 0, (0.0) | 0 | 2, (100) | 100% (7%, 100%) | n/a | | E. cloacae complex | Auto/VITEK 2 | 17 | 3, (17.7) | 8 | 6, (35.3) | 18% (-12%, 44%) | No | | E. cloacae ssp. cloacae | Auto/VITEK 2 | 19 | 3, (15.8) | 5 | 11, (57.9) | 42% (11%, 64%) | Yes | | E. coli | Auto/VITEK 2 | 33 | 11, (33.3) | 6 | 16, (48.5) | 15% (-8%, 36%) | No | | | Manual/VITEK 2 | 6 | 0, (0.0) | 2 | 4, (66.7) | 67% (13%, 90%) | Yes | | | Manual/VITEK 2 Compact | 6 | 0, (0.0) | 1 | 5, (83.3) | 83% (28%, 97%) | Yes | | K. aerogenes | Auto/VITEK 2 | 25 | 10, (40.0) | 6 | 9, (36.0) | -4% (-29%, 22%) | No | K262807 - Page 21 of 24 {22} | | Manual/VITEK 2 | 1 | 0, (0.0) | 0 | 1, (100) | 100%(-12%, 100%) | n/a | | --- | --- | --- | --- | --- | --- | --- | --- | | | Manual/VITEK 2Compact | 1 | 0, (0.0) | 0 | 1, (100) | 100%(-12%, 100%) | n/a | | K. oxytoca | Auto/VITEK 2 | 10 | 2, (20.0) | 3 | 5, (50.0) | 30%(-11%, 60%) | No | | | Manual/VITEK 2 | 1 | 0, (0.0) | 1 | 0, (0.0) | 0%(-79%, 79%) | n/a | | | Manual/VITEK 2Compact | 1 | 0, (0.0) | 1 | 0, (0.0) | 0%(-79%, 79%) | n/a | | K. pneumoniae | Auto/VITEK 2 | 23 | 8, (34.8) | 6 | 9, (39.1) | 4%(-22%, 30%) | No | | | Manual/VITEK 2 | 4 | 1, (25.0) | 1 | 2, (50.0) | 25%(-32%, 66%) | No | | | Manual/VITEK 2Compact | 4 | 1, (25.0) | 1 | 2, (50.0) | 25%(-32%, 66%) | No | | K. pneumoniae spp. pneumoniae | Auto/VITEK 2 | 37 | 10, (27.0) | 9 | 18, (48.7) | 22%(0%, 41%) | No | | | Manual/VITEK 2 | 6 | 3, (50.0) | 1 | 2, (33.3) | -17%(-56%, 32%) | No | | | Manual/VITEK 2Compact | 6 | 2, (33.3) | 2 | 2, (33.3) | 0%(-44%, 44%) | No | | M. morganii | Auto/VITEK 2 | 2 | 1, (50.0) | 0 | 1, (50.0) | 0%(-57%, 57%) | n/a | | M. morganii spp.morganii | Auto/VITEK 2 | 1 | 0, (0.0) | 0 | 1, (100) | 100%(-12%, 100%) | n/a | | P. mirabilis | Auto/VITEK 2 | 2 | 1, (50.0) | 0 | 1, (50.0) | 0%(-57%, 57%) | n/a | | P. vulgaris | Auto/VITEK 2 | 1 | 1, (100) | 0 | 0, (0.0) | -100%(-100%, 12%) | n/a | | P. stuartii | Auto/VITEK 2 | 18 | 2, (11.1) | 4 | 12, (66.7) | 56%(24%, 74%) | Yes | | | Manual/VITEK 2 | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | | Manual/VITEK 2Compact | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | S. marcescens | Auto/VITEK 2 | 52 | 19, (36.5) | 13 | 20, (38.5) | 2%(-16%, 20%) | No | K262807 - Page 22 of 24 {23} | | Manual/VITEK 2 | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | --- | --- | --- | --- | --- | --- | --- | --- | | | Manual/VITEK 2 Compact | 0 | 0, (0.0) | 0 | 0, (0.0) | 0 | n/a | | P. aeruginosa | Auto/VITEK 2 | 168 | 12, (7.1) | 69 | 87, (51.8) | 45% (36%, 53%) | Yes | | | Manual/VITEK 2 | 18 | 1, (5.6) | 11 | 6, (33.3) | 28% (1%, 51%) | No | | | Manual/VITEK 2 Compact | 18 | 0, (0.0) | 12 | 6, (33.3) | 33% (9%, 56%) | Yes | A trend toward higher MIC values was observed for C. koseri, E. cloacae ssp. cloacae, E. coli, P. stuartii, and P. aeruginosa when compared to the CLSI broth microdilution reference method, as summarized in Table 9. The following statement is included as footnote to the performance table in the device labeling to address the observed trending: VITEK 2 AST-Gram Negative Ceftazidime/Avibactam MIC values tended to be in exact agreement or at least one doubling dilution higher when testing Pseudomonas aeruginosa, Citrobacter koseri, Enterobacter cloacae spp. cloacae, Providencia stuartii, and Escherichia coli as compared to the CLSI reference broth dilution method. ### Testing/Reporting MICs for Species Not Listed in the Indications for Use For this review, the interpretive criteria are applied to the organisms/organism groups according to the FDA STIC website. As required under 511A(b)(2)(C)(ii)(I) of the Federal Food, Drug and Cosmetic Act, the following statement was added to the package insert to address testing and reporting of species not listed in the Indications for Use Per the FDA-Recognized Susceptibility Test Interpretive Criteria website, the safety and efficacy of antimicrobial drugs, for which antimicrobial susceptibility is tested by this AST device, may or may not have been established in adequate and well-controlled clinical trials for treating clinical infections due to microorganisms outside of those found in the indications and usage in the drug label. The clinical significance of susceptibility information in those instances is unknown. The approved labeling for specific antimicrobial drugs provides the uses for which the antimicrobial drug is approved. ### 2. Matrix Comparison: Not applicable. ### C Clinical Studies: #### 1. Clinical Sensitivity: K262807 - Page 23 of 24 {24} Not applicable. 2. Clinical Specificity: Not applicable. 3. Clinical Cut-Off Not applicable. 4. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable. # D Expected Values/Reference Range: Table 10: FDA-Recognized Interpretive Criteria | Antimicrobial | Organism | Minimum Inhibitory Concentrations (μg/mL)^{a} | | | | --- | --- | --- | --- | --- | | | | Susceptible | Intermediate | Resistant | | Polymyxin B | *Pseudomonas aeruginosa* | - | ≤2 | ≥4 | | Imipenem | *Acinetobacter* spp. | ≤2 | 4 | ≥8 | | | Enterobacterales | ≤1 | 2 | ≥4 | | | *Pseudomonas aeruginosa* | ≤2 | 4 | ≥8 | | Ceftazidime-avibactam | Enterobacterales | ≤8/4 | - | ≥16/4 | | | *Pseudomonas aeruginosa* | ≤8/4 | - | ≥16/4 | $^{a}$According to FDA STIC Webpage, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria # E. Other Supportive Instrument Performance Characteristics Data: Software and cybersecurity documentation was reviewed and found to be acceptable. # VIII Proposed Labeling: The labeling supports the finding of substantial equivalence for this device. # IX Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision. K262807 - Page 24 of 24
Innolitics
Guidance Recalls

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...